Does AtriCure’s (ATRC) Push Toward Positive EBITDA Recast Its Long‑Term Investment Narrative?

Simply Wall St.

Jan 15

In January 2026, AtriCure reported preliminary 2025 results and issued 2026 guidance, projecting approximately US$600 million to US$610 million in revenue and expecting positive adjusted EBITDA, net ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2603604393"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603604393\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603604393?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","is_english":true,"pubTime":"2026-01-15 16:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603604393","market":"us","top_or_hot":-1,"title":"Does AtriCure’s (ATRC) Push Toward Positive EBITDA Recast Its Long‑Term Investment Narrative?","media":"Simply Wall St.","content":"<div>\n<p>In January 2026, AtriCure reported preliminary 2025 results and issued 2026 guidance, projecting approximately US$600 million to US$610 million in revenue and expecting positive adjusted EBITDA, net ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-atrc/atricure/news/does-atricures-atrc-push-toward-positive-ebitda-recast-its-l\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Does AtriCure’s (ATRC) Push Toward Positive EBITDA Recast Its Long‑Term Investment Narrative?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDoes AtriCure’s (ATRC) Push Toward Positive EBITDA Recast Its Long‑Term Investment Narrative?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-15 16:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-atrc/atricure/news/does-atricures-atrc-push-toward-positive-ebitda-recast-its-l><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In January 2026, AtriCure reported preliminary 2025 results and issued 2026 guidance, projecting approximately US$600 million to US$610 million in revenue and expecting positive adjusted EBITDA, net ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-atrc/atricure/news/does-atricures-atrc-push-toward-positive-ebitda-recast-its-l\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ATRC","symbol_name":"AtriCure公司","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-atrc/atricure/news/does-atricures-atrc-push-toward-positive-ebitda-recast-its-l","article_id":"2603604393","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-atrc/atricure/news/does-atricures-atrc-push-toward-positive-ebitda-recast-its-l","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2603604393","pubTimestamp":1768465474,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In January 2026, AtriCure reported preliminary 2025 results and issued 2026 guidance, projecting approximately US$600 million to US$610 million in revenue and expecting positive adjusted EBITDA, net income, and cash flow, while also highlighting new product launches and completion of enrollment in a key clinical trial.\nThe company simultaneously extended its asset-based revolving credit facility by three years on improved terms, lowering interest costs and adding flexibility that could...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"ATRC":"AtriCure公司","BK4082":"医疗保健设备"},"translate_title":"AtriCure(ATRC)对正EBITDA的推动是否重塑了其长期投资叙事？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATRC":1.5},"content_text":"In January 2026, AtriCure reported preliminary 2025 results and issued 2026 guidance, projecting approximately US$600 million to US$610 million in revenue and expecting positive adjusted EBITDA, net income, and cash flow, while also highlighting new product launches and completion of enrollment in a key clinical trial. The company simultaneously extended its asset-based revolving credit facility by three years on improved terms, lowering interest costs and adding flexibility that could support future commercial and clinical execution. Next, we’ll examine how AtriCure’s expectation of positive adjusted EBITDA around US$80 million to US$82 million influences its investment narrative. These 14 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.AdvertisementAtriCure Investment Narrative RecapTo own AtriCure, you need to believe its surgical solutions and pain management franchise can offset pressures in minimally invasive ablation while the pipeline converts into durable growth and, eventually, sustained profitability. The 2026 guidance for positive adjusted EBITDA of about US$80 million to US$82 million modestly strengthens that case near term, but it does not eliminate the key risk that newer pulsed field ablation catheter technologies could erode parts of its business more quickly than its innovations can compensate. The January 2026 amendment to AtriCure’s US$125 million asset based revolving credit facility, with lower interest costs and looser utilization requirements, is especially relevant here. It gives the company more financial breathing room to support commercial efforts and fund clinical programs like BoxX NoAF, which may be increasingly important if competition tightens in core ablation and appendage management markets. Yet, while the guidance points to improving profitability, investors should also be aware that... Read the full narrative on AtriCure (it's free!)AtriCure's narrative projects $717.8 million revenue and $13.2 million earnings by 2028. This requires 12.8% yearly revenue growth and a $49.6 million earnings increase from -$36.4 million today.Uncover how AtriCure's forecasts yield a $50.00 fair value, a 34% upside to its current price.Exploring Other PerspectivesATRC 1-Year Stock Price Chart Simply Wall St Community members have only two fair value estimates, stretching from about US$0.77 to US$50 per share, underscoring how far apart investor views can be. Against that backdrop, the company’s expectation of positive adjusted EBITDA in 2026 raises important questions about how competition from pulsed field ablation could still shape longer term performance, so it is worth examining several perspectives before forming a view.Explore 2 other fair value estimates on AtriCure - why the stock might be worth as much as 34% more than the current price!Build Your Own AtriCure NarrativeDisagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your AtriCure research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.Our free AtriCure research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate AtriCure's overall financial health at a glance.Ready To Venture Into Other Investment Styles?Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:We've found 12 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 25 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}